1. Epigenetics
    PI3K/Akt/mTOR
  2. AMPK

YLF-466D (Synonyms: C24)

Cat. No.: HY-15840 Purity: 99.16%
Handling Instructions

YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

For research use only. We do not sell to patients.
YLF-466D Chemical Structure

YLF-466D Chemical Structure

CAS No. : 1273323-67-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 462 In-stock
5 mg USD 420 In-stock
10 mg USD 600 In-stock
50 mg USD 1800 In-stock
100 mg USD 2520 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    YLF-466D purchased from MCE. Usage Cited in: Eur J Pharmacol. 2015 Apr 22;760:81-87.

    YLF-466D induces VASP phosphorylation by activating AMPK. (A) Phosphorylation of VASP by YLF-466D (YLF) and (B) its prevention by AMPK inhibitors. WP is treated with CC, ara-A and YLF-466D. Phosphorylation of VASP at Ser239 and Ser157 are measured by immunoblotting with phospho-specific antibodies.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

    IC50 & Target

    AMPK[1]

    In Vitro

    The effect of YLF-466D on platelet AMPK and aggregation are examined to test whether YLF-466D can stimulate AMPK in platelets and thereby suppress aggregation. Platelet AMPK is activated by YLF-466D, which is confirmed with activation-dependent phosphorylation at Thr172. Consistent with this result, YLF-466D inhibits platelet aggregation induced by thrombin. Such inhibition is observed in the aggregation elicited by ADP and collagen as well as thrombin, indicating that the antiaggregatory effect of YLF-466D is not platelet-agonist specific but common, regardless of agonist type. All the effects on AMPK and aggregation are concentration-dependent with the highest efficacy at 150 μM. IC50 against thrombin-, ADP- and collagen-induced aggreation are approximately 84, 55 and 87 μM, respectively[1].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.1462 mL 10.7312 mL 21.4625 mL
    5 mM 0.4292 mL 2.1462 mL 4.2925 mL
    10 mM 0.2146 mL 1.0731 mL 2.1462 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay
    [1]

    Blood is collected from the abdominal aorta of ether anesthetized rats using 3.2% sodium citrate as an anticoagulant (sodium citrate:blood=1:9) and diluted with normal saline (1:1). Blood is incubated with YLF-466D (0, 50, 100 and 150 μM) for 3 min and aggregation is induced with 7.5 μg/mL Collagen. Aggregation is assessed by measuring the impedance change with a whole blood aggregometer[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    465.93

    Formula

    C₂₉H₂₀ClNO₃

    CAS No.

    1273323-67-3

    SMILES

    O=C(O)C1=CC=CC(CN2C(/C(C3=C2C=CC=C3)=C(C4=CC=C(Cl)C=C4)\C5=CC=CC=C5)=O)=C1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.16%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    YLF-466D
    Cat. No.:
    HY-15840
    Quantity: